People

Liquidia Technologies, which recently published positive Phase 1 results for its LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension, has named former Quintiles executive Kevin Gordon as President and Chief Financial Officer. Gordon was most recently Executive VP and Chief Operating Officer of Quintiles. He held various business development … [Read more...] about Kevin Gordon named President and CFO of Liquidia Technologies

OINDP testing specialist Proveris Scientific Corporation has announced the appointment of Chip Leveille as President, effective immediately. Leveille had been the Chief Commercial Officer at the company since April 2016 and previously held positions at BioScale, Helicos, Affymetrix, and Zymark Corporation. Leveille commented, "I am very excited to lead Proveris in … [Read more...] about Proveris Scientific announces appointment of Chip Leveille as President

Spyryx Biosciences, which recently initiated a Phase 2 study of its SPX-101 inhaled SPLUNC1-derived peptide for the treatment of cystic fibrosis, announced that former United Therapeutics CEO Roger Jeffs has joined its board of directors. Jeffs served as President and COO of United Therapeutics from 1998-2014 and as President and CEO from January 2015 until mid … [Read more...] about Roger Jeffs joins board of Spyryx Biosciences

Inhaled drug developer Savara has announced the appointment of Peter Ginsberg as VP of Business Development. Ginsberg was most recently VP of Business Development at BioDelivery Sciences International and had previously held business development positions at a number of companies, including United Therapeutics and Surmodics. He also has experience as a biotechnology … [Read more...] about Savara appoints Peter Ginsberg as VP of Business Development

Neurodyn Cognition (NCI), a Canadian company developing an intranasal therapy for Alzheimer's disease, has named Anthony Giovinazzo as a director and Executive Chairman. Giovinazzo was most recently President and CEO of Cynapsus Therapeutics, which was sold to Sunovion in 2016. NCI's Memogain is described as an intranasal formulation of a prodrug of galantamine, … [Read more...] about Neurodyn Cognition names Anthony Giovinazzo as Executive Chairman

Intranasal cannabinoid developer Therapix Biosciences has announced the appointment of its Chairman of the Board Ascher Shmulewitz as interim CEO. In May 2017, the company said that it was looking for a US-based CEO after Elran Haber stepped down from the role. Therapix licensed an intranasal cannabinoid formulation from Hebrew University’s technology transfer … [Read more...] about Therapix Biosciences appoints Ascher Shmulewitz as interim CEO

AZTherapies, which is developing an inhaled cromolyn/oral ibuprofen combination therapy for the treatment of Alzheimer's disease, has appointed former Pfizer executive Karen Reeves as President and Chief Medical Officer. The company's ALZT-OP1 combination is currently in Phase 3 development. Reeves was most recently VP, Head Global Clinical Submissions Quality and … [Read more...] about Karen Reeves appointed as President and Chief Medical Officer of AZTherapies

Optinose has announced the appointments of Ricci Whitlow as Vice President of Technical Operations, Harry Sacks as VP of Medical Affairs and Corporate Medical Officer, John Peterkins as VP of Market Access, David Fabbri as VP of Sales, and Andrew Muzsi as VP of Marketing. The company's Xhance fluticasone propionate nasal spray for the treatment of nasal polyps … [Read more...] about Optinose announces five appointments

Intranasal etripamil developer Milestone Pharmaceuticals has announced the appointment of Lorenz Muller as Chief Commercial Officer. Muller was most recently VP, Marketing at Exact Sciences Corporation and has previously held positions at Daiichi Sankyo, CV Therapeutics , and Merck. In August 2017, Milestone announced that it had raised $55 million for Phase 3 … [Read more...] about Milestone Pharmaceuticals hires Lorenz Muller as Chief Commercial Officer